GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (NAS:FOLD) » Definitions » Total Current Liabilities

Amicus Therapeutics (Amicus Therapeutics) Total Current Liabilities : $167.7 Mil (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Amicus Therapeutics's total current liabilities for the quarter that ended in Dec. 2023 was $167.7


Amicus Therapeutics Total Current Liabilities Historical Data

The historical data trend for Amicus Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics Total Current Liabilities Chart

Amicus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 128.81 129.68 145.98 139.02 167.69

Amicus Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 139.02 138.39 159.24 169.45 167.69

Amicus Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Amicus Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=110.689+8.324
+Other Current Liabilities+Current Deferred Liabilities
=48.676+0
=167.7

Amicus Therapeutics's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=110.689+8.324
+Other Current Liabilities+Current Deferred Liabilities
=48.676+0
=167.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Amicus Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Amicus Therapeutics (Amicus Therapeutics) Business Description

Traded in Other Exchanges
Address
3675 Market Street, Philadelphia, PA, USA, 19104
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Executives
John F Crowley director, officer: Executive Chairman C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
David Michael Clark officer: Chief People Officer 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Samantha Prout officer: Principal Accounting Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bradley L Campbell director, officer: President and CEO C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ellen Rosenberg officer: General Counsel & Corp. Secy C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08560
Jeff Castelli officer: VP, Program Management 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Harford Simon N.r. officer: Chief Financial Officer AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Michael Raab director 1119 ST PAUL STREET, BALTIMORE MD 21202
Daphne Quimi officer: Chief Financial Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Margaret G Mcglynn director C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100
Burke W Whitman director 13455 NOEL ROAD # 2000, DALLAS TX 75240
Eiry Roberts director C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Hung Do officer: Sr Vice President Discovery C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Michael Aaron Kelly director C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., NEW YORK NY 10016
Jay Barth officer: Chief Medical Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512